The archive
293 stories, newest first — page 6 of 13.
Neurology
ADHERE post hoc data at AAN 2026 show 87.5% of treatment-naive CIDP patients respond early to Vyvgart Hytrulo, challenging IVIG step therapy.
Rayan Salih · 7 min read
Neurology
ADAPT Jr data show 80% of adolescent gMG patients achieved minimal symptom expression by cycle two with efgartigimod at AAN 2026.
Rayan Salih · 7 min read
Innovation & Devices
Pixee Medical’s newly cleared Knee+ NexSight brings augmented reality (AR) into total knee arthroplasty (TKA) in the U.S.
Rayan Salih · 7 min read
Oncology
Sunvozertinib is drawing attention because early reports suggest it may offer progression-free survival benefit as a first-line treatment
Dr. Abu Bakar · 8 min read
Endocrinology & Metabolism
The Trump administration has formally announced a delay of the Medicare Part D implementation of the Center for
Rayan Salih · 13 min read
Neurology
Research to treat Alzheimer’s and other neurodegenerative diseases has been largely focused on removal of amyloid-beta plaques and
Rayan Salih · 10 min read
Neurology
Phase 3 ADAPT OCULUS data at AAN 2026 show efgartigimod significantly improves ocular MG symptoms, supporting a planned FDA sBLA submission for the oMG indication.
Rayan Salih · 2 min read
Oncology
Sexual health after cancer is often overlooked, yet it is a major part of survivorship care.
Dr. Abu Bakar · 8 min read
Oncology
For patients with neoadjuvant HER2+ breast cancer, clinicians are increasingly reconsidering whether carboplatin a platinum chemotherapy drug sometimes
Dr. Abu Bakar · 7 min read
Neurology
Phase 3 ADAPT SERON data at AAN 2026 show efgartigimod significantly improves MG-ADL scores in seronegative gMG patients, with FDA priority review targeting May 10, 2026.
Rayan Salih · 8 min read
Oncology
The Food and Drug Administration has approved the use of Pylarify TruVu, which is an updated version of
Dr. Abu Bakar · 8 min read
Neurology
An early trial of the method involving lithium treatment in people with mild cognitive impairment (MCI) revealed that
Dr. Abu Bakar · 7 min read
Oncology
Trastuzumab Deruxtecan (T-DXd) is now increasingly emerging as the preferred choice for HER2-low metastatic breast cancer patients, and
Dr. Abu Bakar · 9 min read
Oncology
Many people go through cancer treatment and assume that they will return to life’s “new normal,” only to
Dr. Abu Bakar · 7 min read
Oncology
Shorter, higher‑dose radiation therapy schedules are being explored for people with locally advanced breast cancer, and early experience
Dr. Abu Bakar · 6 min read
Oncology
Matched sibling donors remain the top choice for allogeneic hematopoietic cell transplantation (allo-HCT) using post-transplant cyclophosphamide (PTCy) ,
Dr. Abu Bakar · 7 min read
Health Policy
Accountable Care Organization (ACO) savings are central to a decade‑long experiment in paying differently for Medicare care.
Rayan Salih · 7 min read
Innovation & Devices
The MiniMed 780G, an automated insulin delivery system from Abbott, has received FDA clearance to work with the
Rayan Salih · 10 min read
Infectious Disease
A fundamental shift in our understanding of the Major Histocompatibility Complex (MHC) Class I function on target cells
Rayan Salih · 11 min read
Neurology
The U.S. Food and Drug Administration today approved Avlayah (tividenofusp alfa-eknm) for the management of central neurologic manifestations
Rayan Salih · 10 min read
Health Policy
Health care spending is the fastest growing component of state budgets as well as of employer sponsored health
Rayan Salih · 11 min read
Women's Health
The experimental compound IOA-244 is targeted to the p110δ isoform of phosphoinositide 3‑kinase (PI3K) and is active in
Rayan Salih · 2 min read
Mental & Behavioral Health
Interest is rising in psilocybin as a potential treatment for hard-to-treat psychiatric conditions, and numerous clinical trials are
Dr. Abu Bakar · 7 min read
Health Policy
The Medicare Shared Savings Program (MSSP) has been used by the federal government to test value-based payment models
Rayan Salih · 12 min read